Updates are available Correction dated 2024-05-24
Click to view Correction: https://doi.org/10.1186/s13058-024-01833-6
-
Authors
Jacobs, Samuel A.
Wang, Ying
Abraham, Jame
Feng, Huichen
Montero, Alberto J.
Lipchik, Corey
Finnigan, Melanie
Jankowitz, Rachel C.
Salkeni, Mohamad A.
Maley, Sai K.
Puhalla, Shannon L.
Piette, Fanny
Quinn, Katie
Chang, Kyle
Nagy, Rebecca J.
Allegra, Carmen J.
Vehec, Kelly
Wolmark, Norman
Lucas, Peter C.
Srinivasan, Ashok
Pogue-Geile, Katherine L.
- License Information
-
More Information
Article History
Received: 5 October 2023
Accepted: 11 April 2024
First Online: 22 April 2024
Change Date: 24 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13058-024-01833-6
Declarations
:
: Central IRB approval provided by Adverra IRB, Columbia, MD.
: AJ Montero: Honoraria: Celgene, AstraZeneca, OncoSec; Consulting/Advisory Role: New Century Health, Welwaze, Paragon healthcare; Research Funding: F. Hoffmann-La Roche Ltd, Basel, Switzerland; Uncompensated: Roche; Open Payments: . K Quinn: Guardant Health Shareholder. K Chang: Guardant Health Shareholder. RJ Nagy: Guardant Health Shareholder. PC Lucas: Equity interest in AMGEN outside the submitted work. KL Pogue-Geile: Consulting for Bluestar BioAdvisors and Provisional Patents filed both outside the submitted work. All other authors declare no other potential conflicts of interest.
